knowledge -WSS

knowledge

author：fashion 2025-09-27 12:23:09 - browse：5

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： AltruBio raises $225 million to develop ulcerative colitis drug

hotspot

WSS

Empower primary care with adequate payments and technology

It costs an awful lot of money to give away a kidney

FDA approves Sage Therapeutics’ rapid

CDC recommends RSV monoclonal antibody for infants

Primary care doctor shortage won't be solved by free med school tuition

PBM executives asked to testify by House panel

leisure time

knowledge

entertainment

Medical records are filled with copy

Novel spinal cord stimulator treats paralysis without surgery

Alkermes shareholders re

As billionaires fund anti

Activists slam private health insurers over coverage restrictions

The effects of a landmark ruling on DNA ownership are becoming clearer

Bright Health sells Medicare Advantage business to Molina

Chemotherapy before breast cancer surgery might fuel metastasis

DIEP, the 'gold standard' of breast reconstruction, is under threat

Late stage cancers on the rise after pandemic delayed screenings

Wikipedia

FDA scientists endorse Pfizer/BioNTech Covid

Group behind ProMed defends move to subscription

PBM executives asked to testify by House panel

Can gargling with Listerine treat gonorrhea of the mouth?

A controversial new treatment promises to make little people taller

FDA scientists endorse Pfizer/BioNTech Covid

hotspot

hotspot

entertainment

leisure time